Mitoquinone Mesylate – (845959-50-4)

Mitoquinone mesylate, also known as MitoQ, is a synthetic antioxidant specifically designed to target mitochondria, the energy-producing organelles within cells. Developed in New Zealand in the late 1990s, Mitoquinone mesylate is a modified form of coenzyme Q10 with significantly enhanced bioavailability and mitochondrial penetration. This targeted approach allows it to accumulate in mitochondria up to a thousand-fold, providing potent antioxidant protection against oxidative damage.

Mitoquinone mesylate has been studied for its potential in a variety of medical applications, including neurodegenerative diseases, cardiovascular conditions, and metabolic disorders. Research indicates that it may slow the progression of Parkinson’s disease symptoms by targeting antioxidants into the mitochondria, where dysfunction is directly linked to the disease’s pathogenesis. Additionally, studies have shown its efficacy in reducing oxidative stress and inflammation in conditions like acute pancreatitis and sepsis-induced diaphragm dysfunction.

In a humanized mouse model of chronic HIV infection, Mitoquinone mesylate has demonstrated the ability to improve mitochondrial DNA ratios in end organs, suggesting its potential as a treatment for mitochondrial dysfunction in HIV patients. Despite these promising findings, further research is needed to fully understand its therapeutic benefits and clinical applications.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Mitoquinone_mesylate
https://www.medchemexpress.com/Mitoquinone_mesylate.html
https://www.medkoo.com/products/6709
https://pubmed.ncbi.nlm.nih.gov/36958371/
https://go.drugbank.com/salts/DBSALT003175